⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know once you have coronary artery disease (CAD).

Lower is better for your "bad" cholesterol — and we can get it very low, safely. Once you have heart disease, the goal LDL cholesterol is roughly under 55–70 mg/dL (Europe says under 55; the US says under 70, and under 55 if you are very high risk). The lower you get it and the longer it stays low, the fewer heart attacks and strokes.
Statins are the foundation, but they are rarely the whole story. If a high-intensity statin alone doesn't get you to goal, there are now several powerful add-ons: ezetimibe (a cheap pill), PCSK9 inhibitors (injections), inclisiran (a twice-a-year injection), and bempedoic acid (a pill). Most people can reach goal.
Inflammation is now a treatable target. Even with cholesterol controlled, leftover inflammation in artery walls drives risk. Low-dose colchicine 0.5 mg once daily — long used for gout — was FDA-approved in 2023 (brand Lodoco) as the first anti-inflammatory shown to lower heart events. Ask whether it fits you.
Lipoprotein(a) is a once-in-a-lifetime test most people have never had. Lp(a) is an inherited, cholesterol-like particle that raises cardiovascular risk and is not lowered by statins. Because the level is genetically determined and stays essentially stable through life, a single measurement is generally enough — which is why major guidelines support measuring it at least once in adults being risk-assessed. A high level does not change the treatment target so much as the intensity: it is a reason to control the modifiable factors (LDL, blood pressure, smoking) more aggressively. Targeted Lp(a)-lowering drugs are in late-stage trials and none is FDA-approved yet. Ask your doctor: “Have I ever had a lipoprotein(a) level measured, and if not, does my risk profile warrant checking it once?”
The right blood thinners, for the right length of time. Aspirin is standard, often with a second antiplatelet (clopidogrel, ticagrelor, or prasugrel) for a period after a stent or heart attack. For some, low-dose rivaroxaban added to aspirin lowers risk further. The plan is balanced against your bleeding risk — never stop these on your own.
For stable disease, medicines often protect you as well as a stent. A stent is mainly for relieving symptoms or treating an acute event. For preventing future heart attacks in stable disease, excellent medical therapy plus lifestyle works as well as routine stenting (the ISCHEMIA trial).
Cardiac rehab adds years and quality of life — and it is underused. A supervised program of exercise, education, and support independently lowers death and hospitalization after a heart attack, stent, or bypass. If you were not referred, ask for a referral.
If you have diabetes (or obesity), some medicines protect the heart directly. SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular events; semaglutide reduces events even in people with established disease who are overweight without diabetes.
Know the warning signs and call 911. Chest pressure, pain spreading to the arm/jaw/back, shortness of breath, cold sweat, nausea, or lightheadedness — especially if it lasts more than a few minutes — means call emergency services, not "wait and see." Chew an aspirin if advised by the dispatcher and you are not allergic.
The biggest gains come from doing the basics, consistently. Take your medicines every day, don't smoke, move most days, eat a Mediterranean-style diet, control blood pressure and blood sugar, and keep your appointments. Having CAD today is very different from a generation ago — most people who engage with modern prevention live long, full, active lives.

▼ Collapse

Important. This guide is educational and does not replace your own medical team. It describes how care generally works and what questions to raise — your cardiologist and primary care clinician know your arteries, kidneys, bleeding risk, and other conditions, and their advice comes first. Never start, stop, or change a heart medicine (especially blood thinners or antiplatelets) without talking to them.

Overview — What Coronary Artery Disease Is, and Why "Secondary Prevention" Is the Whole Game

Coronary artery disease (CAD) means the arteries that feed your heart muscle have developed atherosclerosis — cholesterol-rich plaque in the artery wall. Plaque can narrow an artery and cause angina (chest pressure or tightness with exertion), and a plaque can suddenly rupture and form a clot, causing a heart attack (myocardial infarction). CAD is the most common cause of death worldwide, but it is also one of the most modifiable diseases in all of medicine.

You may have arrived here through any of several doors: a heart attack, a stent placed during a procedure (PCI), bypass surgery (CABG), a diagnosis of stable angina, or an abnormal stress test or CT scan. Whatever the door, you now share one situation that changes everything about your care: you have established disease. In medicine this shifts you from "primary prevention" (preventing a first event) to "secondary prevention" (preventing the next one). The stakes are higher, and so the targets are more aggressive.

The core idea of this guide. Once you have CAD, the job is not only to treat symptoms. It is to aggressively lower every remaining ("residual") risk factor — cholesterol to a low target, plus attention to inflammation, lipoprotein(a), triglycerides, blood pressure, blood sugar, and clotting — because each event prevented preserves heart muscle and life. Getting your LDL very low early and keeping it low for years yields the greatest benefit.

The "residual risk" idea, in plain language

Imagine your risk of another heart attack as a stack of bricks. Statins remove the biggest brick (LDL cholesterol). But even with a statin, a stack remains. Modern cardiology has learned to name and remove the other bricks:

Residual cholesterol risk — LDL still above target, or other cholesterol-carrying particles (measured by ApoB or non-HDL). Fixed by lowering LDL further with add-on drugs.
Residual inflammatory risk — ongoing inflammation in the artery wall, flagged by a blood test called hs-CRP. Addressed by low-dose colchicine and lifestyle.
Residual lipoprotein(a) risk — an inherited particle statins can't touch. Managed today by controlling everything else; targeted drugs are coming.
Residual triglyceride risk — triglyceride-rich particles, common with diabetes and metabolic syndrome. Addressed by glucose control, lifestyle, and in selected people, icosapent ethyl.
Residual thrombotic (clotting) risk — the tendency to form clots, managed with antiplatelets and, for some, low-dose rivaroxaban.

You will not need every tool. The art of good care is matching the intensity of treatment to your particular stack of bricks — which is why measuring things (your numbers) matters so much.

A realistic but genuinely hopeful picture

A generation ago, a heart attack often meant a frightening, foreshortened life. Today, we can lower "bad" cholesterol further and more safely than ever, we treat inflammation as a risk factor, lipoprotein(a) treatments are arriving, and tailored blood-thinning, cardiometabolic medicines, and cardiac rehabilitation cut the risk of another heart attack dramatically. The tools keep getting better — in just the last year, the first oral PCSK9 inhibitor reported strong trial results and a new once-monthly injectable was approved. Engaging fully with modern secondary prevention is, statistically, one of the most powerful things you can do for your future.

Chronic (stable) coronary disease: known CAD with stable or no symptoms. The focus is relentless risk-factor control and, if needed, angina relief.
After a heart attack (post-MI): the highest-risk window for another event is the first year. This is when getting LDL very low quickly, and using the right antiplatelets, matters most.
After a stent (post-PCI): antiplatelet therapy protects the stent; the duration is tailored to you. Risk-factor control prevents new blockages elsewhere.
After bypass surgery (post-CABG): the grafts and your native arteries both need protection — statins and aspirin are central, and rehab speeds recovery.

The good news is that the prevention playbook is largely the same across all of these — the differences are mostly in the blood-thinner plan and timing.

Which kind of coronary disease do I have, and how severe is it?
What is my single biggest residual risk right now — cholesterol, blood pressure, blood sugar, smoking, or something else?
What is my personal goal for LDL cholesterol, and am I there?
Have all of my "bricks" been measured — LDL, lipoprotein(a), hs-CRP, ApoB, blood pressure, A1c?
What is the one change that would most lower my risk this year?
Who coordinates my care — cardiology, primary care, or a lipid/preventive clinic — and how do I reach them between visits?

Diagnosis & Knowing Your Numbers

Good secondary prevention runs on numbers. You don't need to become a cardiologist, but knowing a handful of your own values — and what they should be — turns you from a passenger into a co-pilot. Keep a simple running list (paper or phone) of the values below with their dates.

The numbers that matter most

Number	What it means	Typical goal with CAD
LDL cholesterol ("bad")	The main driver of plaque.	<55 mg/dL (Europe) or <70 mg/dL (US; <55 if very high risk), and at least a 50% drop from your starting level.
Lipoprotein(a) / Lp(a)	Inherited, statin-resistant risk particle.	Measure once. High is roughly ≥50 mg/dL (≥125 nmol/L). No drug yet lowers it; a high level intensifies everything else.
hs-CRP	A marker of inflammation.	<2 mg/L is favorable. A persistently high level despite controlled LDL flags residual inflammatory risk.
ApoB / non-HDL cholesterol	Counts all the harmful particles, not just LDL.	Useful secondary targets, especially with diabetes or high triglycerides (ApoB often <65–80 mg/dL).
Blood pressure	Pressure load on arteries and heart.	Generally <130/80 mmHg for most with CAD (individualized).
HbA1c (if diabetic)	Average blood sugar over ~3 months.	Often around <7% (individualized; looser in older/frail people).
Triglycerides	Fat particles; high levels add risk.	<150 mg/dL ideal; 150–499 on a statin may prompt icosapent ethyl in selected people.

Ask for your Lp(a) result specifically. Lp(a) is still under-ordered. If you've never had it measured, it is the single most useful "new" number to request — it is a one-time test, it explains a lot of "unexplained" or premature heart disease, and it changes how aggressively your team treats everything else.

How CAD is found and followed

You may encounter several tests. None of them are things you need to memorize, but a quick orientation helps:

Coronary CT angiography (CCTA): a CT scan that pictures the arteries directly — increasingly the first-line test for chest pain.
Coronary artery calcium (CAC) score: a quick CT that quantifies calcified plaque; very useful for refining risk (though once you have known CAD, treatment intensity is already high).
Stress testing (exercise or imaging): looks for areas of the heart not getting enough blood with exertion.
Invasive coronary angiography: the "gold standard" catheter-based look at the arteries, usually when a procedure may be needed.

An important, evidence-based point: once you have stable, known CAD, routine repeat stress tests or scans without new symptoms are generally not recommended. They rarely change management and can lead to unnecessary procedures. Testing should follow a change in how you feel.

Bring your current medicine list with doses, including anything you stopped and why (especially statins — note any muscle symptoms, when they started, and whether they went away off the drug).
Bring your numbers log (LDL, BP readings from home, A1c, weight).
Write your top three questions first — you'll get to them even if time is short.
Ask for a copy of your most recent lipid panel and Lp(a) to keep.
If cost or insurance is an issue with a newer drug, say so directly — there are patient-assistance routes, but only if your team knows.

What is my LDL target now that I have heart disease, and am I at it?
Has my lipoprotein(a) ever been measured? If not, can we check it? If yes, what was it and what does it mean for me?
Should we check hs-CRP and ApoB to look for inflammation and "hidden" particle risk?
How often should my cholesterol be rechecked after a medication change?
Do I actually need another stress test or scan, or are my symptoms stable?
Can I get a printed copy of my key numbers to track at home?

Lowering Your Risk: The Medicines

This is the heart of secondary prevention. We'll go in the order your team usually thinks about them: first cholesterol (statins, then add-ons), then inflammation, then lipoprotein(a) and triglycerides, then blood thinners, then heart-protective diabetes/weight medicines, then blood-pressure and angina drugs. You will not be on all of these. The aim is to assemble the smallest combination that gets your numbers to target.

1. Statins — the foundation

High-intensity statins — atorvastatin 40–80 mg or rosuvastatin 20–40 mg — are first-line for everyone with CAD who can take them. They lower LDL by about half and, across decades of trials, reduce heart attacks, strokes, and death. They are inexpensive, generic, and available everywhere. The benefit is so consistent that statins are the one drug nearly every person with CAD should be on unless there is a true reason not to be.

About muscle aches. Many people fear statin muscle pain, but rigorous "blinded" studies show that the large majority of muscle complaints are not actually caused by the statin — they occur just as often on placebo. This is called the nocebo effect. Most people who think they're "statin-intolerant" can, with the right approach (a different statin, a lower or alternate-day dose, then slowly rebuilding), end up tolerating one. Don't give up on this life-saving class after one bad experience — ask to be re-challenged thoughtfully.

Your liver clears "bad" LDL cholesterol from the blood using little catchers on its surface called LDL receptors. Most of these medicines work by giving your liver more catchers:

Statins make the liver produce less of its own cholesterol, so it puts out more catchers to pull LDL from the blood. This is why they lower LDL so reliably.
Ezetimibe blocks cholesterol absorption from your gut, so less arrives at the liver — nudging it to make even more catchers. It pairs naturally with a statin.
PCSK9 inhibitors (evolocumab, alirocumab; the injections) block a protein called PCSK9 that normally destroys the liver's catchers. Block it, and the catchers survive longer, so far more LDL gets cleared — hence the big extra drop.
Inclisiran reaches the same goal a different way: it quietly tells the liver to stop making PCSK9 in the first place. Because the effect lasts, it's dosed just twice a year after the first two shots.
Bempedoic acid works one step "upstream" of statins in the same cholesterol-making pathway, but it only switches on inside the liver — which is why it generally doesn't cause muscle aches.

The practical takeaway: these are partners, not rivals. Stacking a statin with one or two add-ons is how most people reach a very low LDL — and "very low, kept low for years" is exactly what protects your heart.

2. Add-on cholesterol medicines — getting to goal

If a maximally tolerated statin doesn't get your LDL to target, your team layers on add-ons. The "lower for longer" principle means it's worth being persistent here.

Ezetimibe (a daily pill) is usually added next. It lowers LDL by an additional ~15–20%, is generic and well tolerated, and modestly lowers events on top of a statin.
PCSK9 inhibitors — evolocumab or alirocumab (self-injected every 2–4 weeks) lower LDL by an additional ~50–60% and cut heart attacks and strokes in people with established disease. They are powerful and well tolerated; the main barrier has been cost/coverage.
Inclisiran is a different kind of PCSK9-targeting drug (a "small interfering RNA"). After a starting dose and one at 3 months, it's given just twice a year — convenient for long-term maintenance. It lowers LDL by about half.
Bempedoic acid is a pill that lowers LDL by ~15–25% and reduces events; it is especially useful for people who genuinely cannot take a statin. It does not cause muscle symptoms (it's activated only in the liver).
Newer options (2025–2026): a third-generation once-monthly PCSK9 injection, lerodalcibep (Lerochol), was FDA-approved in December 2025 and is expected to reach the US market in spring 2026; it can be stored at room temperature. And the first oral PCSK9 inhibitor, enlicitide (a once-daily pill), reported strong trial results in 2025–2026 and is under FDA review — if approved, it could make this powerful class far easier to take. (Enlicitide is not yet approved; see Clinical Trials.)

3. Anti-inflammatory therapy — the newest target

Low-dose colchicine 0.5 mg once daily is the first anti-inflammatory medicine proven to lower cardiovascular events, FDA-approved for this use in 2023 (brand Lodoco). In two large trials it reduced the risk of heart attacks, strokes, and the need for procedures in people with coronary disease, on top of statins. It's an option to discuss if your inflammation marker (hs-CRP) is up or your risk remains high despite good cholesterol control.

Colchicine cautions. It should be avoided in severe kidney or liver disease and interacts with certain drugs (some antibiotics and antifungals, and others that affect the same liver pathways). The most common side effect is temporary diarrhea or stomach upset. Grapefruit juice can raise colchicine levels — ask your pharmacist about interactions.

4. Lipoprotein(a) and triglycerides

Lipoprotein(a): No approved drug yet lowers Lp(a) meaningfully (statins don't, and may slightly raise it). If yours is high, the strategy today is to control everything else even more aggressively — lower LDL harder, control blood pressure, never smoke. Several injectable drugs that dramatically lower Lp(a) (pelacarsen, olpasiran, lepodisiran) and an oral one (muvalaplin) are in large trials now; pelacarsen's first outcome results are expected in 2026. These could become the first treatments for a major inherited risk factor — ask your team whether a trial is open near you.

Triglycerides: If your triglycerides stay elevated (roughly 150–499 mg/dL) despite a statin and you have established disease or diabetes, prescription icosapent ethyl (a purified, EPA-only fish-oil-derived medicine, 2 grams twice daily) lowered events in a major trial. Note: ordinary over-the-counter "fish oil" supplements are not the same and have not shown this benefit (see Failed Therapies).

5. Antithrombotic (anti-clotting) therapy

Plaque events are clotting events, so blocking clots is central. There are two families:

Antiplatelets: Aspirin (low dose, e.g., 81 mg) is the backbone for life in most people with CAD. After a stent or heart attack, a second antiplatelet — clopidogrel, ticagrelor, or prasugrel — is added for a period ("dual antiplatelet therapy," or DAPT). How long depends on your bleeding risk and what was done; it can be anywhere from 1 to 12 months, sometimes longer or shorter.
Dual-pathway inhibition: for selected high-risk people (e.g., disease in more than one arterial bed), adding low-dose rivaroxaban 2.5 mg twice daily to aspirin lowered events further in the COMPASS trial — at the cost of somewhat more bleeding.

Never stop antiplatelets on your own. Stopping aspirin or a second antiplatelet too early after a stent can cause a dangerous clot in the stent. If a dentist or surgeon asks you to stop them, have them coordinate with your cardiologist first.

6. Heart-protective diabetes and weight medicines

Two newer classes protect the heart beyond their original purpose:

SGLT2 inhibitors (empagliflozin, dapagliflozin, others) — lower cardiovascular events and protect the heart and kidneys, especially valuable if you also have diabetes, heart failure, or kidney disease.
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) — lower cardiovascular events in people with diabetes; semaglutide also reduced events in people with established heart disease and overweight/obesity without diabetes, while producing major weight loss.

7. Blood-pressure and angina medicines

Controlling blood pressure protects the heart and arteries. ACE inhibitors or ARBs (e.g., lisinopril, losartan) are often used, especially with diabetes, reduced heart function, or after a heart attack. For chest symptoms (angina), beta-blockers, calcium-channel blockers, long-acting nitrates, and ranolazine relieve symptoms and improve exercise tolerance — these treat symptoms and are layered with the risk-lowering drugs above.

Adherence is the master skill. The most powerful medicine is the one you actually take every day. Use a weekly pillbox, link doses to a daily habit (coffee, brushing teeth), set phone alarms, and use pharmacy auto-refill and 90-day supplies. If a side effect bothers you, call before stopping — there is almost always an alternative.

Am I on the strongest statin I can tolerate, and is my LDL at goal?
If I'm not at goal, should we add ezetimibe, a PCSK9 inhibitor, inclisiran, or bempedoic acid?
Could low-dose colchicine lower my risk from inflammation? Is it safe with my kidneys and other medicines?
Should I be on icosapent ethyl for my triglycerides?
Which blood thinners am I on, and for exactly how long? When does my second antiplatelet stop?
Am I a candidate for low-dose rivaroxaban added to aspirin, given my risk and bleeding profile?
Do I qualify for an SGLT2 inhibitor or GLP-1 medicine for heart protection?
Is my blood pressure at goal, and is an ACE inhibitor or ARB right for me?
Are any of my medicines duplicative or causing side effects we could simplify?

Your CAD medicines at a glance — doses, how they are taken, and what to expect

This reference lists usual adult doses drawn from each drug's FDA prescribing information (per label) and the 2023 AHA/ACC Chronic Coronary Disease guideline. Doses are individualized — yours may differ, and only your prescriber sets them. Use this to recognize your own regimen and to ask precise questions, never to self-adjust.

Medicine	What it is for	Typical adult dose (per FDA label)	How taken	What to expect & key evidence
Atorvastatin	High-intensity statin; the LDL-lowering foundation	40 mg or 80 mg once daily	Oral tablet, any time of day	Lowers LDL by about half; fewer events (PROVE-IT trial, 2004; FDA label)
Rosuvastatin	High-intensity statin	20 mg or 40 mg once daily	Oral tablet	Lowers LDL ~50% or more; per FDA label and 2018 AHA/ACC guideline
Ezetimibe	Usual first add-on if LDL not at goal on a statin	10 mg once daily	Oral tablet	Extra ~15-20% LDL drop; fewer events (IMPROVE-IT trial, 2015)
Evolocumab (Repatha)	PCSK9 inhibitor injection; large extra LDL drop	140 mg every 2 weeks, or 420 mg once monthly	Self-injected under the skin	Extra ~60% LDL drop; fewer heart attacks/strokes (FOURIER trial, 2017)
Alirocumab (Praluent)	PCSK9 inhibitor injection	75 mg or 150 mg every 2 weeks	Self-injected under the skin	Fewer events after a recent heart attack (ODYSSEY Outcomes trial, 2018)
Inclisiran (Leqvio)	PCSK9-targeting siRNA; twice-a-year maintenance	284 mg on day 1, again at day 90, then every 6 months	Injection given in clinic	About half the LDL drop of a PCSK9 shot, very convenient (ORION-10/11 trials, 2020; FDA label)
Bempedoic acid (Nexletol)	Non-statin pill; useful if statin cannot be tolerated	180 mg once daily	Oral tablet	~18-25% LDL drop; fewer events in statin-intolerant patients (CLEAR Outcomes trial, 2023)
Colchicine (Lodoco)	Anti-inflammatory; lowers residual inflammatory risk	0.5 mg once daily	Oral tablet	~23-31% fewer events on top of a statin (COLCOT trial 2019; LoDoCo2 trial 2020; FDA-approved for this use 2023)
Icosapent ethyl (Vascepa)	Purified EPA for high triglycerides on a statin	2 g twice daily (4 g/day total)	Oral capsules with food	25% fewer events in selected patients (REDUCE-IT trial, 2019)
Aspirin	Lifelong antiplatelet backbone in most with CAD	81 mg once daily	Oral tablet	Fewer clot events; 2023 AHA/ACC guideline
Clopidogrel	Second antiplatelet (DAPT) after stent/heart attack	75 mg once daily (after a 300-600 mg load)	Oral tablet	Protects the stent; duration is individualized (2023 AHA/ACC guideline)
Ticagrelor (Brilinta)	More potent second antiplatelet (DAPT)	90 mg twice daily first year, then often 60 mg twice daily	Oral tablet	Fewer events after ACS (PLATO trial 2009; PEGASUS trial 2015)
Prasugrel (Effient)	Potent second antiplatelet after PCI for ACS	10 mg once daily (5 mg if low body weight/older)	Oral tablet	Fewer events after stenting for ACS (TRITON trial, 2007)
Rivaroxaban (Xarelto)	Very-low-dose, added to aspirin in selected high-risk people	2.5 mg twice daily plus aspirin 81 mg	Oral tablet	Fewer events, some extra bleeding (COMPASS trial, 2017)
Empagliflozin (Jardiance)	SGLT2 inhibitor; heart/kidney protection	10 mg once daily	Oral tablet	Fewer CV deaths in diabetes (EMPA-REG trial, 2015)
Dapagliflozin (Farxiga)	SGLT2 inhibitor	10 mg once daily	Oral tablet	Fewer heart-failure/CV events (DECLARE trial, 2019)
Semaglutide (Wegovy)	GLP-1 agonist; events + weight in overweight CAD	Titrated to 2.4 mg once weekly	Self-injected weekly	~20% fewer events without diabetes (SELECT trial, 2023)
Metoprolol succinate	Beta-blocker; angina, post-MI, arrhythmia	25 mg up to 200 mg once daily	Oral tablet	Symptom and rhythm control; per FDA label
Lisinopril	ACE inhibitor; blood pressure, post-MI, diabetes	10 mg up to 40 mg once daily	Oral tablet	Protects heart/kidneys; 2023 AHA/ACC guideline
Losartan	ARB alternative when an ACE inhibitor causes cough	50 mg up to 100 mg once daily	Oral tablet	Blood-pressure control; per FDA label
Ranolazine (Ranexa)	Anti-anginal that does not lower heart rate/BP	500 mg up to 1000 mg twice daily	Oral tablet	Relieves stubborn angina; per FDA label
Isosorbide mononitrate	Long-acting nitrate for chronic angina	30 mg up to 120 mg once daily	Oral tablet (with a daily nitrate-free interval)	Prevents angina; do not combine with PDE5 inhibitors
Amlodipine	Calcium-channel blocker for angina and blood pressure	5 mg or 10 mg once daily	Oral tablet	Relieves angina, lowers BP; per FDA label
Nitroglycerin (sublingual)	Rescue for acute angina	0.4 mg under the tongue, may repeat every 5 minutes up to 3 times	Sublingual tablet or spray	If pain persists after the first dose, call 911; per FDA label
Pantoprazole	Stomach protection (PPI) for GI-bleed risk on DAPT	40 mg once daily	Oral tablet	Lowers GI bleeding on antiplatelets; 2023 AHA/ACC guideline

How to read this table. "Per label" means the dose comes from the drug's FDA prescribing information; "trial" names (in parentheses) are the studies that proved the benefit — you can look each up by its trial ID in the Landmark Trials table under Support & Resources. If your dose differs, that is usually deliberate — ask your prescriber why, rather than changing anything yourself.

How the medicines work together — synergies and stacking

Modern prevention is deliberately a stack: each drug removes a different "brick" of residual risk, and the combined (synergistic) effect is larger than any single drug. Understanding how they amplify one another helps the plan make sense.

Statin + ezetimibe. The statin makes the liver pull in more LDL; ezetimibe blocks the gut from resupplying cholesterol. Stacking them lowers LDL more than either alone, which is why this is the usual first combination (IMPROVE-IT trial, 2015).
Statin + PCSK9 inhibitor (or inclisiran). Statins raise the liver's LDL "catchers"; PCSK9 blockade keeps those catchers from being destroyed. The combined effect can drive LDL below 40 mg/dL — the "very low, kept low" state that most protects arteries (FOURIER trial, 2017).
LDL-lowering + colchicine. These treat two different bricks — cholesterol and inflammation. Colchicine's benefit in the LoDoCo2 trial (2020) was on top of statins, so the effects add rather than overlap.
Antiplatelet + LDL control + blood-pressure control. Fewer clots, less plaque growth, and less arterial stress compound into a much larger total risk reduction than any one lever — the core logic of the 2023 AHA/ACC guideline.
SGLT2 inhibitor + GLP-1 agonist (if diabetic). They protect the heart through different mechanisms and can be combined for an additive cardiometabolic benefit.

The flip side of stacking: watch the interactions. The same "combine for benefit" logic means some pairings must be avoided. Grapefruit juice amplifies both certain statins and colchicine to unsafe levels. Nitrates plus a PDE5 inhibitor (see the safety section) can crash blood pressure. Adding low-dose rivaroxaban to aspirin amplifies bleeding as well as protection. Always keep one clinician and one pharmacist seeing your whole list.

Numeric stop, hold, and monitor rules — know these before you need them

Most heart medicines are meant for the long haul, and the biggest danger is usually stopping the protective ones (statins, antiplatelets) without a plan. But a few clear, numeric rules tell you when to hold a drug and call. Learn them now, calmly, rather than in a crisis.

Statins — the rhabdomyolysis rule. Stop if you develop severe, unexplained muscle pain or weakness together with dark (tea- or cola-colored) urine, and call your clinician the same day — this rare reaction (rhabdomyolysis) needs a blood test (creatine kinase). Ordinary mild aches without dark urine are usually not dangerous; call before stopping.
Statins — re-challenge as a trial period. If you stopped for muscle symptoms, a supervised trial period on a different statin or an alternate-day, low dose (for example rosuvastatin 5 mg twice weekly) is how most "intolerant" people find one they tolerate.
Colchicine — the GI and kidney rule. Discontinue if you develop severe or bloody diarrhea, and do not use colchicine if your kidney function (eGFR) is very low or you take strong interacting drugs (some antibiotics/antifungals) without your team adjusting it.
Antiplatelets/DAPT — the do-NOT-stop rule. There is no self-stop rule here. Never stop aspirin or a second antiplatelet after a stent on your own, even for a dental or minor procedure — premature discontinuation can cause stent thrombosis (a heart attack). The only "stop" is one your cardiologist directs.
Bleeding — when to call urgently. On any antiplatelet or blood thinner, seek care for black or tarry stools, vomiting blood, or bleeding that will not stop after 10 minutes of pressure. This is a reason to call, not to silently stop a life-saving drug.
Beta-blockers — taper, do not quit. When to stop a beta-blocker is a decision for your clinician: stopping abruptly can trigger rebound angina or a heart attack, so it is tapered over 1-2 weeks.
ACE inhibitor/ARB — the pregnancy and potassium rule. These must be stopped before or at conception (fetal harm); your clinician also monitors potassium and kidney function after starting or increasing the dose.

Procedures, Angina & Advanced Care

Procedures restore blood flow through severely blocked arteries. They are powerful and sometimes life-saving — but understanding what they do and don't do protects you from both under- and over-treatment.

Stents (PCI) and bypass surgery (CABG)

Angioplasty with a stent (PCI): a catheter opens a blocked artery and props it open with a small mesh tube. Essential during a heart attack and excellent for relieving angina that medicines can't control.
Coronary artery bypass grafting (CABG): open-heart surgery that routes blood around blockages using vessels from elsewhere in your body. Often preferred for extensive disease, left-main disease, or alongside diabetes with multi-vessel disease.

The most misunderstood fact in CAD. For stable coronary disease, a stent mainly relieves symptoms — it does not, on average, prevent more heart attacks or extend life better than excellent medical therapy plus lifestyle (the large ISCHEMIA trial). This is genuinely good news: if you feel well, medicines and rehab may protect you just as well, without a procedure. Stents and bypass remain critical for acute events (heart attacks), certain high-risk anatomy (like left-main disease), and symptoms that medicines can't control.

When a procedure clearly helps

During a heart attack (to open the blocked artery quickly).
Angina that limits your life despite good medical therapy.
Specific high-risk anatomy your team identifies (e.g., left-main or severe multi-vessel disease, especially with reduced heart function).

When angina persists — and "advanced" angina

If you have ongoing chest symptoms, your team will optimize antianginal medicines (beta-blockers, calcium-channel blockers, nitrates, ranolazine) and reassess. Some people have microvascular angina (the tiny vessels, not the big arteries, are the problem) or vasospastic angina (artery spasm) — these are real, treatable, and often missed; they're managed mainly with medicines rather than stents. If symptoms are refractory, specialized centers offer additional options.

After a procedure: prevention doesn't pause — it intensifies

A stent or bypass treats a blockage; it does not cure the disease in the rest of your arteries. The period right after a procedure is exactly when aggressive secondary prevention pays off most: get LDL very low, take your antiplatelets exactly as prescribed, start cardiac rehab, and don't smoke. Think of the procedure as buying you time and symptom relief — and prevention as protecting the investment.

Call emergency services immediately for:

Chest pressure, tightness, squeezing, or pain — often central, lasting more than a few minutes or coming and going.
Pain spreading to the arm(s), jaw, neck, back, or stomach.
Shortness of breath, with or without chest discomfort.
Cold sweat, nausea, lightheadedness, or unusual fatigue.

Women, older adults, and people with diabetes may have subtler symptoms (fatigue, breathlessness, nausea) without classic chest pain. When in doubt, call 911 — do not drive yourself. If the dispatcher advises and you are not allergic, chew one regular aspirin.

Do I need a stent or bypass, or are medicines and lifestyle enough to protect me?
If a procedure is offered, is it to relieve symptoms or to improve my survival? What does the evidence say for my situation?
What is the plan for my antiplatelet medicines after the procedure, and for how long?
Could my chest symptoms be microvascular or vasospastic angina rather than a blockage?
What angina medicines can we try or adjust before considering another procedure?
What symptoms should prompt me to call you — versus call 911?

Lifestyle, Cardiac Rehab & Staying Well

Medicines do a lot, but lifestyle is not the "soft" part of prevention — it independently lowers events and makes every medicine work better. And cardiac rehabilitation, specifically, is one of the most underused life-extending interventions in all of cardiology.

Cardiac rehabilitation — ask for the referral

Cardiac rehab is a supervised, structured program (typically 36 sessions over ~12 weeks, plus home-based and tele-rehab options) of monitored exercise, education, risk-factor coaching, and emotional support after a heart attack, stent, or bypass. It independently lowers death and rehospitalization, improves fitness and mood, and helps you regain confidence. Despite this, it is referred to and attended far less often than it should be — especially among women, older adults, and rural patients. If you weren't referred, ask. If transportation or schedule is a barrier, ask specifically about home-based or virtual rehab.

The Mediterranean-style diet

The best-studied heart pattern emphasizes vegetables, fruit, whole grains, legumes, nuts, olive oil, and fish, with less red and processed meat, refined carbohydrates, and added sugar. You don't need perfection — consistent, mostly-good choices beat short-lived strictness. Practical anchors: cook with olive oil, eat fish a couple of times a week, make half your plate vegetables, swap refined grains for whole, and treat processed meats and sugary drinks as occasional.

Move most days

Aim, over time and with your team's clearance, for about 150 minutes a week of moderate activity (like brisk walking), plus some strength work twice weekly. Reducing sitting time matters too. After an event, cardiac rehab is the safest on-ramp to building this up.

Smoking cessation — the single highest-yield change

If you smoke, quitting is the most powerful thing you can do for your heart — risk begins falling within weeks and continues for years. This is hard, and willpower alone is the least effective method. Combining counseling (including quitlines) with medication (nicotine replacement, varenicline, or bupropion) dramatically raises success. Ask your team for a real cessation plan, not just advice to quit.

Mental health and emotional recovery after a heart attack

Depression and anxiety are common after a cardiac event — affecting up to roughly a fifth of people — and they're not a sign of weakness. They matter medically: untreated depression independently worsens outcomes and makes it harder to take medicines, attend rehab, and make lifestyle changes. The good news is that it's treatable, and cardiac rehab itself often lifts mood.

Watch for: persistent sadness or hopelessness, loss of interest in things you used to enjoy, sleep or appetite changes, irritability, or anxiety and fear of "the next event" that keeps you from activity. A short screening questionnaire is a normal part of good cardiac care — ask for one if it hasn't come up.

When to speak up promptly. Tell your team if low mood lasts more than two weeks, if anxiety is stopping you from exercising or living normally, or at any point if you have thoughts of not wanting to be here. Support — counseling, therapy, and when appropriate medication — works, and seeking it is part of protecting your heart.

Special notes: women and younger adults

Women with coronary disease are, on average, under-recognized, under-treated, and under-referred to cardiac rehab — not because the biology is different but because symptoms and care patterns differ. Heart-attack symptoms in women more often include fatigue, shortness of breath, nausea, or jaw/back discomfort rather than classic crushing chest pain, which can delay care. Women are also more likely to have conditions like microvascular or vasospastic angina (problems in the small vessels or artery spasm) that standard angiograms can miss. If you're a woman with ongoing symptoms and a "clean" angiogram, ask specifically about these. Make sure you're offered the same aggressive LDL lowering, the same rehab referral, and the same follow-up as anyone else.

Younger adults with CAD (especially in their 30s–50s) should push hard on the "why so early?" question. A high lipoprotein(a), familial hypercholesterolemia (an inherited very-high-cholesterol condition), and a strong family history of premature heart disease are common, under-tested explanations. Identifying these changes how aggressively you're treated and prompts cascade screening of close relatives, who may carry the same risk unknowingly. Don't accept "you're too young for this" — get Lp(a) measured, ask about FH, and treat your numbers to secondary-prevention targets for the long haul.

Pregnancy and heart disease: what women with CAD should know

Pregnancy raises cardiac output by 40–50% and stresses the cardiovascular system substantially. For women with coronary artery disease — or for any woman of reproductive age concerned about heart health — several points are important.

Spontaneous coronary artery dissection (SCAD) — a tear in the inner lining of a coronary artery — is the most common cause of heart attack during and shortly after pregnancy. It is distinct from ordinary plaque-related CAD and is often missed if clinicians aren't looking for it. SCAD is usually managed conservatively (not with stenting, which can worsen the tear); the majority of women recover well. If you are young, pregnant, or recently postpartum and experience chest pain, shortness of breath, or severe fatigue, seek emergency care and mention pregnancy status explicitly.
Pre-pregnancy medication planning — several standard CAD medications must be modified before or during pregnancy. Statins are contraindicated in pregnancy and should be stopped before conception. ACE inhibitors and ARBs can harm fetal kidney development and must be stopped at or before conception. Your cardiologist needs to plan a safe medication transition before you try to conceive — do not stop medications on your own.
Aspirin during pregnancy — low-dose aspirin (81 mg) is generally continued for secondary cardiac prevention during pregnancy, in consultation with both your cardiologist and obstetrician; it may also reduce preeclampsia risk.
After delivery (postpartum) — the cardiovascular system remains under stress for weeks after birth. Contact your team immediately for any chest pain, shortness of breath, leg swelling, or unusual fatigue in the postpartum period. Breastfeeding women need a medication review: statins should remain held while breastfeeding; most beta-blockers and low-dose aspirin are acceptable; ACEi use requires a risk-benefit discussion.

If you have CAD and are planning a pregnancy, schedule a pre-conception cardiology appointment well in advance. A team approach including cardiology and maternal-fetal medicine (high-risk obstetrics) gives you and your baby the best care.

Vaccines and other "quiet" protections

Influenza vaccination lowers cardiovascular events in people with heart disease and is recommended yearly; ask your team about flu, COVID-19, pneumococcal, and RSV vaccines as appropriate for you. Treat sleep apnea if you have it, manage stress, and keep dental health up — these all feed back into heart health.

Your secondary-prevention targets at a glance

These are common goals for people with established coronary disease. Yours may be individualized — confirm them with your team and write your own numbers next to each.

Risk factor	Common goal with CAD
LDL cholesterol	<55–70 mg/dL, and at least halved from your starting level
Blood pressure	Generally <130/80 mmHg
HbA1c (if diabetic)	Often <7% (looser if older/frail)
Smoking	Zero — complete cessation, with help
Physical activity	~150 min/week moderate activity + strength 2×/week
Weight	Healthy range for you; even 5–10% loss helps if overweight
Lipoprotein(a)	Measured at least once; if high, everything else controlled harder

Your secondary-prevention checklist

A simple way to make sure nothing falls through the cracks. Review it with your team once or twice a year.

☐ I'm on the strongest statin I can tolerate, and my LDL is at goal (or we have a plan with add-ons to get there).
☐ My lipoprotein(a) has been measured once.
☐ We've discussed whether low-dose colchicine fits me.
☐ I know exactly which blood thinners I take and for how long.
☐ My blood pressure and (if diabetic) blood sugar are at goal.
☐ If I have diabetes, obesity, heart failure, or kidney disease, we've discussed an SGLT2 inhibitor and/or GLP-1 medicine.
☐ I've completed or am enrolled in cardiac rehab.
☐ I don't smoke (or I have an active quit plan with medication + counseling).
☐ I'm up to date on flu and other recommended vaccines.
☐ My mood and stress have been checked, and I have support if needed.
☐ I take my medicines daily and have a refill system that prevents gaps.
☐ I know my warning signs and when to call 911.

What to track at home

Blood pressure: a validated home cuff, taken correctly (seated, arm supported, after 5 minutes rest), is invaluable. Log readings to share.
Weight: a sudden rise can signal fluid retention (tell your team).
Symptoms: note any new or changing chest discomfort, breathlessness, or exercise limits.
Medication adherence: a simple checklist or app keeps the daily basics on track.

Can you refer me to cardiac rehabilitation? Is a home-based or virtual option available?
How much and what kind of exercise is safe for me right now?
What dietary changes would most help my specific numbers?
Can you help me build a real quit-smoking plan with medication and counseling?
Should I be screened for depression, anxiety, or sleep apnea?
Which vaccines should I have this year?
What are my personal targets for blood pressure, LDL, weight, and (if diabetic) HbA1c?
(For women) Could my symptoms be microvascular or vasospastic angina, and am I getting the same aggressive prevention as anyone else?
(For younger adults) Could lipoprotein(a) or familial hypercholesterolemia explain my early disease — and should my relatives be screened?

Support & Resources

For Caregivers — Notes & Practical Tips

Caregivers are part of the prevention team. Your steady, practical support measurably improves adherence and recovery. Here's where you can help most.

Set up a weekly pillbox together and refill it on a fixed day; pair pills with a daily routine.
Use a 90-day supply and pharmacy auto-refill to avoid gaps — gaps in antiplatelets are especially risky after a stent.
Keep an up-to-date medicine list (with doses) on the fridge and on a phone — bring it to every appointment and the ER.
If a side effect comes up, encourage calling the team before stopping anything — especially blood thinners.

Learn the warning signs (chest pressure; pain to arm/jaw/back; shortness of breath; cold sweat; nausea; unusual fatigue), and the rule: more than a few minutes, or severe — call 911, don't drive them. Know where the aspirin is. Keep the cardiology and primary-care numbers somewhere obvious. Trust your instinct that "something is wrong" — especially with women, older adults, and people with diabetes, who may not have classic chest pain.

Cardiac rehab attendance: help arrange rides and scheduling; attending a session or two with them early can boost confidence.
Heart-healthy eating: cooking together makes change stick — shift the whole household's pattern rather than singling them out.
Smoking cessation: support the plan without nagging; if you smoke too, quitting together helps both of you.
Tracking numbers: help take and log home blood pressure and weight; bring the log to visits.
After a procedure: watch for warning signs, help with activity limits, and offer steady encouragement — recovery is as much emotional as physical.
Watch your own wellbeing: caregiver burnout is real. Accept help, take breaks, and use support resources too.

Clinical Trials — The Frontier You Can Join

Trials are how the next generation of prevention gets proven, and several of the most exciting ones in cardiology right now are in secondary prevention. Participation is voluntary, can give access to tomorrow's therapies, and helps everyone. Some major active programs:

Lipoprotein(a)-lowering outcome trials — the headline story. Lp(a)HORIZON (pelacarsen, NCT04023552) has its first results expected in 2026; OCEAN(a)-Outcomes (olpasiran, NCT05581303) completes around the end of 2026; ACCLAIM-Lp(a) (lepodisiran, NCT06292013) is enrolling. These test whether lowering Lp(a) actually prevents heart attacks.
Oral PCSK9 inhibitor — enlicitide's cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756), is testing whether a once-daily PCSK9 pill reduces events.

How to search for trials. Use ClinicalTrials.gov (search "coronary artery disease" or a drug name and your state), ask your cardiologist or a university heart center whether a relevant trial is open, and ask specifically about Lp(a) trials if your Lp(a) is high. Bring the trial's NCT number to your team to discuss fit and safety.

Failed & De-adopted Therapies — What Has Not Worked

You'll encounter confident online claims about heart "cures" and supplements. Honesty about what rigorous testing has disproven is as important as what it has proven. Things that did not hold up in good trials:

Niacin (high-dose vitamin B3) add-on: despite improving lipid numbers, it did not reduce events when added to statins, and caused harms. Abandoned for this purpose.
"CETP inhibitor" drugs (early generation): torcetrapib and others raised HDL ("good" cholesterol) but failed to help (torcetrapib caused harm). HDL-raising for its own sake is not a strategy.
Routine over-the-counter fish oil / mixed omega-3 supplements: the STRENGTH trial of a mixed EPA/DHA product was neutral. Only prescription icosapent ethyl (pure EPA) showed benefit, in a specific population. OTC fish oil is not a substitute.
Fibrates broadly (e.g., pemafibrate): the PROMINENT trial lowered triglycerides but did not reduce events. Fibrates are not a general CAD-prevention tool.
Antioxidant vitamins (E, C, beta-carotene), and routine chelation: no proven benefit for preventing heart events; some harm signals. Not recommended.
Hormone replacement therapy to prevent heart disease: does not prevent (and may increase) cardiac events when used for that purpose.
Routine stenting of stable blockages to prevent heart attacks: as above (ISCHEMIA), this does not, on average, beat good medical therapy for event prevention in stable disease.

About supplements generally. "Natural" is not the same as "safe" or "effective." Red yeast rice contains a statin-like compound (monacolin K) at unpredictable doses and carries the same risks as a statin without the quality control. Grapefruit juice can dangerously raise levels of some statins and of colchicine. St. John's Wort can weaken blood thinners (ticagrelor, rivaroxaban) and statins. Always tell your team and pharmacist about every supplement — and treat supplements as additions to discuss, never substitutes for proven care.

Specialty Center Directory

Phone numbers change; confirm before relying on them. This is a starting map, not an endorsement, and not exhaustive.

Mountain West & Utah

University of Utah Health Cardiovascular Center (Salt Lake City) — preventive cardiology & lipid clinic (PCSK9 inhibitors, inclisiran, Lp(a) evaluation, statin-intolerance pathways), interventional cardiology (PCI), cardiac surgery (CABG), and cardiac rehab. Main: 801-585-0500 (verify).
Intermountain Medical Center Heart Institute (Murray, UT) — a major regional cardiovascular center: full secondary prevention, advanced lipid management, revascularization, and cardiac rehab across the Wasatch Front. Main: 801-507-4700 (verify).
VA Salt Lake City Health Care System (George E. Wahlen VA) — cardiology and cardiac rehabilitation for veterans. Main: 801-582-1565 (verify).
Community-hospital cardiac rehab programs (University of Utah, Intermountain, and others) — supervised exercise/education after a heart attack, stent, or bypass; ask any of the above to refer you.

US National Centers of Excellence

Cleveland Clinic Heart, Vascular & Thoracic Institute (Cleveland, OH) — preventive cardiology and a major Lp(a)/residual-risk research hub. 800-223-2273 (verify).
Brigham and Women's Hospital (Boston, MA) — home of much landmark lipid and inflammation research. 617-732-5500 (verify).
Mayo Clinic (Rochester, MN; also AZ & FL) — comprehensive preventive cardiology and lipid clinics. 507-284-2511 (verify).
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease (Baltimore, MD) — prevention-focused. 410-955-5000 (verify).
Mount Sinai / Cedars-Sinai / Stanford / UTSW — all have strong preventive-cardiology and lipid programs.

Veterans (VA)

VA medical centers nationwide provide cardiology, lipid management, and cardiac rehab. The VA/DoD has its own clinical practice guidelines for lipid management and CAD. Ask your VA primary-care team for a cardiology and lipid-clinic referral, and about service connection if your CAD may be related to service (e.g., certain exposures). Find facilities at va.gov.

Canada

Major academic heart centers (e.g., Montreal Heart Institute — the home of the COLCOT colchicine trial; Toronto General / Peter Munk Cardiac Centre; University of Ottawa Heart Institute; Vancouver General) offer full secondary-prevention and lipid services. Canadian Cardiovascular Society (CCS) guidelines apply. Drug coverage note: PCSK9 inhibitors, inclisiran, and icosapent ethyl are available but subject to provincial/private formulary criteria; low-dose colchicine for CVD was approved by Health Canada. Coverage rules vary by province.

International (selected)

Europe: ESC/EAS-affiliated centers across the UK and Europe apply the more aggressive LDL <55 mg/dL target; the UK's NICE governs access to newer agents.
Imperial College / national lipid clinics (UK), centers in Germany, Italy, the Netherlands, and others run dedicated Lp(a) and familial-hypercholesterolemia clinics.
Many countries have familial hypercholesterolemia (FH) networks — worth seeking if heart disease runs young in your family.

International Access & Regulatory Landscape (Patient View)

What's available — and affordable — depends on where you live.

Cheap and available almost everywhere: statins, ezetimibe, aspirin, clopidogrel, and most blood-pressure medicines are inexpensive generics worldwide.
Newer agents (PCSK9 inhibitors, inclisiran, icosapent ethyl, cardiovascular colchicine): approved across most high-income countries (US FDA, EMA in Europe, Health Canada, PMDA in Japan, NMPA in China), but coverage rules and out-of-pocket cost differ a lot. In the US, expect prior-authorization steps; manufacturer patient-assistance programs can help.
LDL targets differ by region: Europe (ESC/EAS) targets LDL <55 mg/dL (and <40 for recurrent events); the US (2023 AHA/ACC) uses <70, with <55 for very-high-risk. If you travel or move, your "goal" may be stated differently — the direction (lower is better) is the same.
Lipoprotein(a): reported in different units (mg/dL vs nmol/L) in different places; a high level matters everywhere. Lp(a) is a particularly important driver of premature heart disease in South Asian and African-ancestry populations.
Domestic innovation: China and some other countries have approved home-grown PCSK9 inhibitors and lipid drugs not sold in the West.
Cardiac rehab is evidence-based but underused globally; tele- and home-based programs are expanding access.
Brand-new (2025–2026): lerodalcibep (Lerochol), a once-monthly PCSK9 injection, was FDA-approved in December 2025 (US launch expected spring 2026); the oral PCSK9 pill enlicitide is under FDA review. Availability elsewhere will follow over time.

What Your Medicines Cost — and a Dated Action Clock

Cost is one of the most common reasons a good prevention plan quietly falls apart. Here are real, current US cash and coverage figures (verify your own pharmacy and plan), the coverage path when a drug is expensive, verbatim scripts, and a time-phased checklist to bring to your team.

The foundation drugs are inexpensive

High-intensity statin: generic atorvastatin 40–80 mg and rosuvastatin 20–40 mg are among the cheapest drugs in the pharmacy. A 30-day supply is about $4 on Walmart's generic-drug list and roughly $4 to $30 with a GoodRx cash coupon (GoodRx lists atorvastatin 40 mg near $29.65 and rosuvastatin 20 mg as low as $2 to $15, as of July 2026).
Second antiplatelet: generic clopidogrel 75 mg — the usual partner to aspirin after a stent — is about $4.50 for 30 tablets with a GoodRx cash coupon (versus roughly $98 average retail; GoodRx, July 2026). Aspirin is a few dollars over the counter.

Script. Ask your pharmacist: "What is the cash price on GoodRx or your own discount program for my statin and clopidogrel, and is a 90-day supply cheaper?"

The expensive add-on: PCSK9 inhibitor injections

If you need a PCSK9 inhibitor to reach your LDL goal, the sticker price is high but the amount you actually pay is usually much lower through coverage and manufacturer help:

Evolocumab (Repatha): list price is about $5,850 per year (Amgen's reduced list price, in effect since 2019). With the manufacturer copay card, eligible commercially insured patients may pay as little as $5 per month (about $25 for a 1-month or $50 for a 3-month supply) — Repatha.com, 2026.
Alirocumab (Praluent): also about $5,850 per year list price (Sanofi/Regeneron, since 2019); the MyPRALUENT copay card can bring commercially insured patients to as little as $0 to $25 per month (up to $3,500 per year in assistance) — Praluent.com, 2026.

The coverage path, step by step. (1) Medicare Part D or your commercial drug plan covers PCSK9 inhibitors, inclisiran, and icosapent ethyl, but usually requires prior authorization — your clinic documents your LDL, your statin history, and your diagnosis. (2) If you are denied, ask your team to appeal; approvals often succeed on the second try. (3) Manufacturer copay cards (Repatha, Praluent) sharply cut cost for commercially insured patients — by law they cannot be used with Medicare or Medicaid. (4) If you have Medicare or no insurance, ask about the manufacturer's patient-assistance program and nonprofit foundations.

Script. Ask your cardiologist: "If I need a PCSK9 inhibitor, can your team file the prior authorization, and am I eligible for the manufacturer copay card or a patient-assistance program?"

Script. Ask your clinician: "If cost is the reason I'm not on an add-on cholesterol medicine, what is the cheapest option that still gets me to my LDL goal?"

Your dated action clock

A time-phased checklist for the weeks and months after a diagnosis, heart attack, stent, or bypass. Confirm the specifics with your own team.

In the first 48 hours / before discharge: confirm you leave with a high-intensity statin, your antiplatelet plan in writing, and a cardiac-rehab referral. Ask exactly how long to stay on your second antiplatelet (after a stent, DAPT is often 6–12 months per the 2023 AHA/ACC Chronic Coronary Disease guideline).
Within 2 weeks: book your follow-up visit and your cardiac-rehab intake; fill every prescription (use a 90-day supply if it is cheaper); set daily reminders and a pillbox.
In the first month: start cardiac rehab once cleared; get your one-time lipoprotein(a) drawn if it has never been done; solve any cost or coverage problem now rather than later.
At the first 4 weeks to 12 weeks: recheck your LDL against goal (under 70 mg/dL, or under 55 if you are very high risk, per the 2023 AHA/ACC guideline; Europe uses under 55). If you are not there, this is the visit to discuss adding ezetimibe, a PCSK9 inhibitor, inclisiran, or bempedoic acid.
By month 3 and ongoing: confirm blood pressure under 130/80, A1c on target if you have diabetes, and that you have not stopped any antiplatelet without cardiology. After a stent, do not stop DAPT early — premature discontinuation can cause stent thrombosis (a heart attack).

A fuller cost and coverage table (US cash and coverage, 2026)

Prices move and depend on your plan and pharmacy — treat these as a map, and always confirm your own numbers. Figures are US cash/GoodRx or manufacturer list prices as of July 2026.

Medicine	Rough US cost (2026)	How to lower it
Atorvastatin 40-80 mg	About $4-$30 for 30 days (GoodRx/Walmart list, 2026)	Generic; ask for the pharmacy discount price and a 90-day supply
Rosuvastatin 20-40 mg	About $2-$15 for 30 days (GoodRx, 2026)	Generic; discount coupon
Ezetimibe 10 mg	About $5-$15 for 30 days (GoodRx, 2026)	Generic since 2017
Clopidogrel 75 mg	About $4.50 for 30 days with a coupon (vs ~$98 retail; GoodRx, 2026)	Generic; discount coupon
Ticagrelor (Brilinta) 90 mg	~$450-$550/month brand; a generic is now available and cheaper	Ask whether generic ticagrelor is stocked; manufacturer savings card
Colchicine (Lodoco) 0.5 mg	Roughly $80-$100/month brand (2026); generic colchicine is cheaper	Ask about generic 0.6 mg colchicine and manufacturer copay help
Evolocumab (Repatha)	~$5,850/year list; as little as $5/month with copay card (Repatha.com, 2026)	Prior authorization + manufacturer copay card (commercial insurance)
Alirocumab (Praluent)	~$5,850/year list; as little as $0-$25/month with copay card (Praluent.com, 2026)	Prior authorization + MyPRALUENT copay card
Inclisiran (Leqvio)	~$3,250 per dose, roughly $6,500 first year then ~$6,500/year list (2026)	Given in clinic; often billed to medical benefit; ask about assistance
Bempedoic acid (Nexletol) 180 mg	Roughly $400-$450/month list (2026)	Manufacturer savings program; prior authorization
Icosapent ethyl (Vascepa) 2 g twice daily	Generic ~$40-$90/month cash; brand higher (GoodRx, 2026)	Ask for generic icosapent ethyl
Empagliflozin / dapagliflozin 10 mg	Roughly $550-$650/month brand (2026); coverage varies	Manufacturer savings card; check formulary tier
Semaglutide (Wegovy) 2.4 mg	Roughly $1,300/month list (2026); highly plan-dependent	Prior authorization; manufacturer savings for commercial plans

Script. Ask your pharmacist: "Is there a generic or a cheaper equivalent for each of my heart medicines, and would a 90-day supply lower my total cost?"

Script. Ask your clinician: "If cost is the only reason I am not on a recommended medicine, what is the least expensive option that still gets me to my LDL goal?"

Landmark trials behind this guide (with trial IDs, dated)

These are the major randomized trials that shaped modern secondary prevention. Trial IDs are listed as of July 2026 so you can look any of them up on ClinicalTrials.gov and bring the number to your team.

Trial	What it tested	Headline result	Reported	Trial ID
IMPROVE-IT	Ezetimibe added to a statin after ACS	Lower LDL, modestly fewer events	2015	NCT00202878
FOURIER	Evolocumab (PCSK9) added to a statin	~15% fewer heart attacks/strokes	2017	NCT01764633
ODYSSEY Outcomes	Alirocumab (PCSK9) after a recent ACS	Fewer events and fewer deaths	2018	NCT01663402
ORION-10	Inclisiran (twice-yearly siRNA) in ASCVD	~50% LDL reduction, durable	2020	NCT03399370
CLEAR Outcomes	Bempedoic acid in statin-intolerant patients	Fewer events without a statin	2023	NCT02993406
COLCOT	Colchicine 0.5 mg daily after a heart attack	23% fewer CV events	2019	NCT02551094
CANTOS	Canakinumab (anti-inflammatory) proof of concept	Inflammation is a treatable target	2017	NCT01327846
REDUCE-IT	Icosapent ethyl 2 g twice daily with high triglycerides	25% fewer events	2019	NCT01492361
COMPASS	Low-dose rivaroxaban 2.5 mg twice daily plus aspirin	Fewer events, more bleeding	2017	NCT01776424
ISCHEMIA	Routine stenting vs medicines for stable CAD	No survival benefit from routine stenting	2020	NCT01471522
EMPA-REG OUTCOME	Empagliflozin (SGLT2) in diabetes with CVD	Fewer CV deaths	2015	NCT01131676
SELECT	Semaglutide in overweight CAD without diabetes	~20% fewer CV events	2023	NCT03574597
Lp(a)HORIZON	Pelacarsen to lower lipoprotein(a) 80 mg monthly	First Lp(a) outcome results expected 2026	ongoing	NCT04023552
OCEAN(a)-Outcomes	Olpasiran (siRNA) to lower lipoprotein(a)	Outcome data expected around end of 2026	ongoing	NCT05581303
ACCLAIM-Lp(a)	Lepodisiran to lower lipoprotein(a)	Enrolling; tests whether lowering Lp(a) prevents events	ongoing	NCT06292013
CORALreef Outcomes	Enlicitide, an oral PCSK9 pill	Testing whether a daily pill lowers events	ongoing	NCT06008756

Why the trial IDs matter. A trial ID (an "NCT number") is the fingerprint of a study — it lets you and your clinician find the exact protocol, who was eligible, and the real results, instead of relying on a headline. If your Lp(a) is high, the Lp(a)HORIZON, OCEAN(a), and ACCLAIM-Lp(a) trials are the ones to ask about.

Verbatim questions and scripts to use at each decision point

Actionable prevention often comes down to asking one precise question at the right moment. These are word-for-word scripts you can read aloud or hand over. They are written to equip you, not to tell your team what to do — the decision is always theirs and yours together.

Getting your numbers and targets right

Ask your cardiologist: "What is my personal LDL goal now that I have coronary disease — under 70 or under 55 mg/dL — and what is my most recent number?"
Ask your clinician: "Has my lipoprotein(a) ever been measured? If not, can we draw it once, and what would a high result change?"
Ask your team: "Can I get a printed copy of my LDL, ApoB, hs-CRP, blood pressure, and A1c to track at home?"

Getting to your LDL goal

Ask your cardiologist: "If I am not at my LDL goal on the strongest statin I tolerate, should we add ezetimibe first, and then a PCSK9 inhibitor, inclisiran, or bempedoic acid?"
Ask your pharmacist: "If I need a PCSK9 inhibitor, can you help file the prior authorization, and am I eligible for the manufacturer copay card?"
Ask your clinician: "I had muscle aches on a statin — can we try a supervised re-challenge on a different statin or a low, alternate-day dose before giving up on the class?"

Inflammation, triglycerides, and lipoprotein(a)

Ask your cardiologist: "My risk still feels high with my cholesterol controlled — could low-dose colchicine 0.5 mg daily help, and is it safe with my kidneys and other medicines?"
Ask your clinician: "My triglycerides are still high on a statin — am I a candidate for icosapent ethyl 2 g twice daily?"
Ask your cardiologist: "My lipoprotein(a) is high — is there an Lp(a)-lowering trial open near me, and what should we control even more tightly in the meantime?"

Blood thinners and procedures

Ask your cardiologist: "Exactly which antiplatelets am I on, and for how long — when does my second antiplatelet stop?"
Ask your cardiologist: "A dentist or surgeon wants me to stop my blood thinner — can you talk to them first so I do not stop it unsafely?"
Ask your clinician: "Given my bleeding risk, should I be on a stomach-protecting PPI like pantoprazole 40 mg while I take DAPT?"
Ask your cardiologist: "Is a stent likely to help my symptoms, improve my survival, or neither — and what does the evidence say for my specific situation?"

Cardiometabolic and blood-pressure protection

Ask your clinician: "Given my diabetes (or heart failure or kidney disease), do I qualify for an SGLT2 inhibitor or a GLP-1 medicine for heart protection?"
Ask your cardiologist: "Is my blood pressure at goal under 130/80, and is an ACE inhibitor or ARB right for me?"

Rehab, lifestyle, and recovery

Ask your team: "Can you refer me to cardiac rehabilitation, and is a home-based or virtual option available if transportation is hard?"
Ask your clinician: "Can you help me build a real quit-smoking plan with medication and counseling, not just advice to quit?"
Ask your clinician: "Should I be screened for depression, anxiety, or sleep apnea after my cardiac event?"

Special situations

Ask your cardiologist: "I am a woman with ongoing symptoms and a clean angiogram — could this be microvascular or vasospastic angina, and am I getting the same aggressive prevention as anyone else?"
Ask your clinician: "I developed heart disease young — could lipoprotein(a) or familial hypercholesterolemia explain it, and should my close relatives be screened?"
Ask your team: "Before I am discharged, can you confirm I am leaving with a high-intensity statin, my antiplatelet plan in writing, and a cardiac-rehab referral?"

Glossary

Atherosclerosis: cholesterol-rich plaque building up in artery walls.
CAD / coronary artery disease: atherosclerosis in the heart's own arteries.
Secondary prevention: preventing the next event in someone who already has disease.
LDL cholesterol: "bad" cholesterol; the main driver of plaque. Lower is better.
ApoB: a count of all the harmful cholesterol-carrying particles.
Lipoprotein(a) / Lp(a): an inherited, statin-resistant risk particle; measure once.
hs-CRP: a blood marker of inflammation.
Statin: the foundational LDL-lowering drug (e.g., atorvastatin, rosuvastatin).
PCSK9 inhibitor: a powerful LDL-lowering drug (injection, or now a pill in trials).
Inclisiran: a twice-yearly injection that lowers LDL.
Ezetimibe / bempedoic acid: pill add-ons that lower LDL.
Colchicine: an anti-inflammatory pill (0.5 mg daily) that lowers heart events.
Icosapent ethyl: a prescription purified fish-oil (EPA) medicine for high triglycerides.
Antiplatelet: a clot-preventing drug (aspirin, clopidogrel, ticagrelor, prasugrel).
DAPT: dual antiplatelet therapy — two antiplatelets together for a period.
PCI / stent: catheter procedure to open and prop open a blocked artery.
CABG: coronary artery bypass surgery.
SGLT2 inhibitor / GLP-1 receptor agonist: diabetes/weight medicines that also protect the heart.
ISCHEMIA: the landmark trial showing medicines often equal stents for event prevention in stable disease.
MACE: "major adverse cardiovascular events" — the heart attacks/strokes/deaths trials count.

Key References & Sources

This guide draws on major guidelines and landmark trials, including:

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Circulation 2023).
2024 ESC Guidelines for the Management of Chronic Coronary Syndromes (European Heart Journal 2024).
2019 ESC/EAS Guidelines for the Management of Dyslipidaemias; 2018 AHA/ACC Cholesterol Guideline.
Landmark trials: 4S and PROVE-IT (statins); IMPROVE-IT (ezetimibe); FOURIER (evolocumab); ODYSSEY OUTCOMES (alirocumab); ORION (inclisiran); CLEAR Outcomes (bempedoic acid); LoDoCo2 and COLCOT (colchicine); CANTOS (canakinumab, proof of concept); REDUCE-IT (icosapent ethyl); COMPASS (rivaroxaban + aspirin); ISCHEMIA and COURAGE (revascularization vs medical therapy); EMPA-REG, DECLARE, LEADER, SELECT (SGLT2i/GLP-1).
National Lipid Association and ACC scientific statements on lipoprotein(a).
Patient education: American Heart Association (heart.org), MedlinePlus (NLM), and ClinicalTrials.gov for trials.

Final reminder. This is general education, current as of June 2026, and medicine evolves. Your own cardiologist, primary-care clinician, and pharmacist — who know your full situation — are the right source for decisions about your care. Use this guide to ask better questions, not to self-treat.

Is there a clinical trial — especially an Lp(a) trial — that might fit me?
Are any of the supplements I take interacting with my heart medicines?
Can you connect me with cardiac rehab, a dietitian, a smoking-cessation program, or mental-health support?
If cost is a barrier to a recommended medicine, what assistance programs exist?
Who do I call between visits, and what counts as urgent versus an emergency?

Clinical Trials — The Frontier You Can Join

Ask your care team whether a clinical trial is appropriate for your situation, and search ClinicalTrials.gov for current studies. See also the resources listed elsewhere in this guide.

A Research Guide forCAD

⚡ Quick Start — If You Read Nothing Else

Overview — What Coronary Artery Disease Is, and Why "Secondary Prevention" Is the Whole Game

The "residual risk" idea, in plain language

A realistic but genuinely hopeful picture

Diagnosis & Knowing Your Numbers

The numbers that matter most

How CAD is found and followed

Lowering Your Risk: The Medicines

1. Statins — the foundation

2. Add-on cholesterol medicines — getting to goal

3. Anti-inflammatory therapy — the newest target

4. Lipoprotein(a) and triglycerides

5. Antithrombotic (anti-clotting) therapy

6. Heart-protective diabetes and weight medicines

7. Blood-pressure and angina medicines

Your CAD medicines at a glance — doses, how they are taken, and what to expect

How the medicines work together — synergies and stacking

Numeric stop, hold, and monitor rules — know these before you need them

Procedures, Angina & Advanced Care

Stents (PCI) and bypass surgery (CABG)

When a procedure clearly helps

When angina persists — and "advanced" angina

After a procedure: prevention doesn't pause — it intensifies

Lifestyle, Cardiac Rehab & Staying Well

Cardiac rehabilitation — ask for the referral

The Mediterranean-style diet

Move most days

Smoking cessation — the single highest-yield change

Mental health and emotional recovery after a heart attack

Special notes: women and younger adults

Pregnancy and heart disease: what women with CAD should know

Vaccines and other "quiet" protections

Your secondary-prevention targets at a glance

Your secondary-prevention checklist

What to track at home

Support & Resources

For Caregivers — Notes & Practical Tips

Clinical Trials — The Frontier You Can Join

Failed & De-adopted Therapies — What Has Not Worked

Specialty Center Directory

Mountain West & Utah

US National Centers of Excellence

Veterans (VA)

Canada

International (selected)

International Access & Regulatory Landscape (Patient View)

What Your Medicines Cost — and a Dated Action Clock

The foundation drugs are inexpensive

The expensive add-on: PCSK9 inhibitor injections

Your dated action clock

A fuller cost and coverage table (US cash and coverage, 2026)

Landmark trials behind this guide (with trial IDs, dated)

Verbatim questions and scripts to use at each decision point

Glossary

Key References & Sources

Clinical Trials — The Frontier You Can Join

⚠️ Safety Warnings & Critical Drug Risks

Nitroglycerin + PDE5 Inhibitors — Absolutely Contraindicated Combination

Dual Antiplatelet Therapy (DAPT) After Stent — Never Stop Without Cardiologist Approval

Important Medication Precautions

A Research Guide for
CAD